Condition: Pancreatic Ductal Adenocarcinoma · Non-small Cell Lung Cancer · Colorectal Cancer · Sponsor: Eli Lilly and Company
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| University of California, Los Angeles (UCLA) | Santa Monica, California, United States | Recruiting |
| Sarah Cannon Research Institute at HealthOne | Denver, Colorado, United States | Recruiting |
| Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute | Orlando, Florida, United States | Recruiting |
| Emory University School of Medicine | Atlanta, Georgia, United States | Recruiting |
| Community Health Network | Indianapolis, Indiana, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| South Texas Accelerated Research Therapeutics (START) Midwest | Grand Rapids, Michigan, United States | Recruiting |
| New York University (NYU) Langone Medical Center | New York, New York, United States | Recruiting |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06586515